Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola
20 oct. 2014 12h00 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government...
Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
29 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...
Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
22 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
15 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Intranasal Seasonal...
Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon(R) and Ampligen(R) Against the Ebola Virus
10 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it expanded its Collaborative Research Agreement to test...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
08 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that the Company and USAMRIID scientists have agreed to test...
Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2014
11 août 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the six months ended June 30, 2014. The net loss (including non-cash effects) was...
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
04 août 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
22 juil. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print])...
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
14 juil. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced a strategic alliance to develop multiple projects with Bioclones...